Updated results of PEANUT trial: Pembrolizumab and nabpaclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)

被引：0
|
作者：
Bottiglieri, A. [1 ]
Bravo, W. Ferrari [1 ]
Rametta, A. [1 ]
Provenzano, L. [1 ]
Raggi, D. [2 ]
Marandino, L. [2 ]
Fare, E. [3 ]
Longo, V. [1 ]
Guadalupi, V. [1 ]
Stellato, M. [1 ]
Verzoni, E. [1 ]
Sepe, P. [1 ]
Claps, M. [1 ]
Calareso, G. [4 ]
Alessi, A. [5 ]
Cattaneo, L. [6 ]
Colecchia, M. [7 ]
Procopio, G. [1 ]
Necchi, A. [2 ]
Giannatempo, P. [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[2] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy
[3] Osped Civile Legnano, Dept Med Oncol, Legnano, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Dept Intervent Radiol, Milan, Italy
[5] Fdn IRCCS Ist Nazl Tumori, Dept Nucl Med, Milan, Italy
[6] Fdn IRCCS Ist Nazl Tumori, Adv Diagnost Dept, Milan, Italy
[7] IRCCS Osped San Raffaele, Dept Pathol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2370P
引用
收藏
页码：S1206 / S1206
页数：1
相关论文
共 50 条
  • [41] Vinflunine in Platinum-Pretreated Patients With Locally Advanced or Metastatic Urothelial Carcinoma Results of a Large Phase 2 Study
    Vaughn, David J.
    Srinivas, Sandy
    Stadler, Walter M.
    Pili, Roberto
    Petrylak, Daniel
    Sternberg, Cora N.
    Smith, David C.
    Ringuette, Sarah
    de Wit, Edwin
    Pautret, Virginie
    George, Claude
    CANCER, 2009, 115 (18) : 4110 - 4117
  • [42] Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis
    Apolo, Andrea B.
    Ellerton, John A.
    Infante, Jeffrey R.
    Agrawal, Manish
    Gordon, Michael S.
    Aljumaily, Raid
    Gourdin, Theodore
    Dirix, Luc
    Lee, Keun-Wook
    Taylor, Matthew H.
    Schoeffski, Patrick
    Wang, Ding
    Ravaud, Alain
    Manitz, Juliane
    Pennock, Gregory
    Ruisi, Mary
    Gulley, James L.
    Patel, Manish R.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [43] Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma
    Mullane, Stephanie A.
    Werner, Lillian
    Guancial, Elizabeth A.
    Lis, Rosina T.
    Stack, Edward C.
    Loda, Massimo
    Kantoff, Philip W.
    Choueiri, Toni K.
    Rosenberg, Jonathan
    Bellmunt, Joaquim
    CLINICAL GENITOURINARY CANCER, 2016, 14 (04) : 352 - 359
  • [44] Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
    Bantounou, Maria A.
    Plascevic, Josip
    MacDonald, Lewis
    Wong, Man Chun
    O'Connell, Neasa
    Galley, Helen F.
    CURRENT UROLOGY, 2023, 17 (04) : 271 - 279
  • [45] Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.
    Powles, Thomas
    Loriot, Yohann
    Ravaud, Alain
    Vogelzang, Nicholas J.
    Duran, Ignacio
    Retz, Margitta
    De Giorgi, Ugo
    Oudard, Stephane
    Bamias, Aristotelis
    Koeppen, Hartmut
    Leng, Ning
    Kadel, Edward E.
    Hegde, Priti S.
    Cui, Na
    Shen, Xiaodong
    Derleth, Christina Louise
    Green, Marjorie C.
    Banchereau, Romain
    Mariathasan, Sanjeev
    Van Der Heijden, Michiel Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [46] Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.
    Koshkin, Vadim S.
    Sonpavde, Guru P.
    Hwang, Clara
    Mellado, Begona
    Tomlinson, Gareth
    Shimura, Masashi
    Chisamore, Michael Jon
    Gil, Maciej
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [47] Study EV-103: Update on durability results and long term outcome of enfortumab vedotin plus pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).
    Friedlander, Terence W.
    Milowsky, Matthew I.
    Bilen, Mehmet Asim
    Srinivas, Sandy
    Mckay, Rana R.
    Flaig, Thomas W.
    Hoimes, Christopher J.
    Balar, Arjun Vasant
    Henry, Elizabeth
    Petrylak, Daniel P.
    Sasse, Carolyn
    Kataria, Ritesh S.
    Yu, Yao
    Carret, Anne-Sophie
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study
    Van der Heijden, M. S.
    Loriot, Y.
    Duran, I.
    Ravaud, A.
    Retz, M. M.
    Vogelzang, N. J.
    Nelson, B.
    Wang, J.
    Shen, X.
    Powles, T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] A Podcast on Platinum Eligibility and Treatment Sequencing in Platinum-Eligible Patients with Locally Advanced or Metastatic Urothelial Carcinoma
    Gupta, Shilpa
    Moon, Helen H. -S.
    Sridhar, Srikala S.
    TARGETED ONCOLOGY, 2024, : 483 - 494
  • [50] Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210
    Balar, Arjun Vasant
    Dreicer, Robert
    Loriot, Yohann
    Perez-Gracia, Jose Luis
    Hoffman-Censits, Jean H.
    Petrylak, Daniel Peter
    Van Der Heijden, Michiel Simon
    Ding, Beiying
    Shen, Xiaodong
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345